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COMPOUNDS OF USE IN THE TREATMENT

?ring of brain neurons. The neurons can ?re at up to four
times their normal rate. As a result, epileptic seizures are an
overstimulation of the normal neuronal processes that con

OF EPILEPSY, SEIZURE, AND
ELECTROCONVULSIVE DISORDERS

trol brain function.

Anti-epileptic drugs are available for treating epilepsies,

RELATED APPLICATIONS

but these agents have a number of shortcomings. For
instance, the agents are often poorly soluble in aqueous and
biological ?uids or are extremely hygroscopic. Of even

This application is a divisional of application Ser. No.
10/345,387 ?led Jan. 16, 2003 noW abandoned.
This application claims the bene?t of US. Provisional

greater importance is that patients often become refractory

Patent Application No. 60/348,366 ?led Jan. 16, 2002,
Which is incorporated herein by reference.

to a drug over time. In addition, many anti-epileptic agents
cause unWanted side effects, neurotoxicities, and drug inter
actions. Even While being treated With one or a combination

FIELD OF THE INVENTION

of the anti-epileptic drugs currently in clinical use, 30% of
epileptic patients still experience seizures. As more anti
epileptic drugs are developed, the clinician Will have

The present invention relates to bridged dianilino com

pounds and pharmaceutical compositions and method of use
thereof for the prevention and treatment of epilepsies, sei
zures, and other electroconvulsive disorders. Speci?cally,

expanded pharmaceutical options When designing an effec
tive treatment protocol for each patient. Accordingly, a

continuing need exists for pharmaceutical compositions that

this invention relates to the use of 4,4'-thiodianiline, 4,4'

diaminobenzophenone, 4,4'-methylenedianiline, 4,4'-diami

20

nodiphenyl ether, or (3-aminophenyl)-(4-aminophenyl)
amine and related compounds, and preparations thereof, for
the prevention, palliation and/or treatment of seizures, con
duction disturbances and electroconvulsive disorders of all
types, manifestations and origins, in humans and in animals.

treat or prevent epilepsy and its associated symptoms With
minimal side effects.

After experimentation and investigation, it has been dis
covered that oral and intraperitoneal administration of a

therapeutic compound comprising formula (I) beloW to mice
25

and rats resulted in profound and reproducible anticonvul
sant or antiepileptic activity in animal modes of seizure
disorders. It has further been discovered that these com
pounds do not shoW acute neurotoxic effects at the levels

BACKGROUND OF THE INVENTION

required for a therapeutic response.
Epilepsy is a general term describing a group of central
nervous system disorders that are characterized by recurrent
seizures that are the outWard manifestation of excessive

and/or hyper-synchronous abnormal electrical activity of

An advantage and object of the present invention is a
pharmaceutical composition useful for the treatment, pre

neurons of the cerebral cortex and other regions of the brain.
This abnormal electrical activity can be manifested as motor,

convulsion, sensory, autonomic, or psychic symptoms.
Epilepsy affects millions of people WorldWide, and over

vention and/or amelioration of disorders related to and
35

including epilepsy, seizure, and other electroconvulsive dis
orders.

2.5 million individuals in the United States. For the purposes

According to the present invention, the foregoing objects

of clinical assessment, it is useful to classify patients accord
ing to the type of seizure the patient experiences. As

described in The Pharmacological Basis ofTherapeuZics, 9th

SUMMARY OF THE INVENTION

30

and advantages are achieved in part by a therapeutic com

pound, including resolved enantiomers, diastereoisomers,
40

Ed. (McGraW-Hill) [1], there are tWo classes of seizures:

tautomers, salts, solvates and polymorphic forms thereof,

having the folloWing formula (I):

partial seizures and generalized seizures. Partial seizures
consist of focal and local seizures. Partial seizures are

further classi?ed as simple partial seizures, complex partial
seizures and partial seizures secondarily generalized. Gen

(1)
45

eralized seizures are classi?ed as convulsive and noncon

vulsive seizures. They are further classi?ed as absence

(previously referred to as ‘petit mal’) seizures, atypical
absence seizures, myoclonic seizures, clonic seizures, tonic
seizures, tonic-clonic seizures, and atonic seizures.
Hundreds of epileptic syndromes have been de?ned as
disorders characterized by speci?c symptoms that include

50

Wherein R1, R2, R3, and R4, are each independently selected
from the group consisting of hydrogen, hydroxy, amino,
phenyl, a substituted or unsubstituted Cl_1O alkyl, C3_1O

epileptic seizures. These include, but are not limited to,

absence epilepsy, psychomotor epilepsy, temporal lobe epi
lepsy, frontal lobe epilepsy, occipital lobe epilepsy, parietal

55

lobe epilepsy, Lennox-Gastaut syndrome, Rasmussen’s
encephalitis, childhood absence epilepsy, Ramsay Hunt

Syndrome type II, benign epilepsy syndrome, benign infan
tile encephalopathy, benign neonatal convulsions, early
myoclonic encephalopathy, progressive epilepsy and infan

stituted or unsubstituted C1_ 10 alkoxyl and a substituted or

unsubstituted C1_ 10 acyl; and X is selected from the group

consisting of 40*, iSi, iN(H)i, iSei, iSii,
%H=CHi, 4CECi, iN=Ni, iN=CHi,
60

tile epilepsy. A patient may suffer from any combination of

It is believed that the characteristic seizures of epilepsy

are caused by the disordered, synchronous, and rhythmic

%H=Ni, %(S)i, iN(H)S(O)i, iN(H)SO2i,
iN(H)Oi, iN(H)Si, iS(O)i, iSOzi, iPO4i,
iSi(O)i, iC(O)i, 4CH2i, 4CF2i, and a covalent

different types of seizures. Partial seizures are the most
common, and account for approximately 60% of all seizure

types. Regardless of the type of epilepsy, seizures signi?
cantly limit the autonomy of the patient.

branched alkyl, a substituted or unsubstituted C3_8
cycloalkyl, a substituted or unsubstituted arylalkyl, a sub

bond.
Another object of the present invention is a method of
65

treating, ameliorating, or preventing epilepsy, seizure or
electroconvulsive disorders in a subject in need thereof. In
an embodiment of the present invention, the method com
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prises administering an effective amount of 4,4'-thiodi

aniline,

4,4'-diaminobenZophenone,

4,4'-methylenedi

aniline, 4,4'-diaminodiphenyl ether, or (3-aminophenyl)-(4
aminophenyl) amine, or a pharmaceutically acceptable salt

iSi(O)i, iC(O)i, 4CH2i, 4CF2i, and a covalent

or complex thereof to a subject in need of treatment,
amelioration, or prevention of such disorders.

bond
In an embodiment of the present invention, 4,4'-thiodi

aniline,

Further according to the invention, the foregoing objects

(4-aminophenyl)

aniline, or (3-aminophenyl)-(4-aminophenyl) amine, or a
20

Embodiments of the present invention include a pharma
ceutical composition comprising a dose of about 0.1 mg/kg

none, 4,4'-methylenedianiline, 4,4'-diaminodiphenyl ether,
25

into

a

useful in the prevention, palliation, and/or treatment of
seiZures, conduction disturbances and electroconvulsive dis
orders of all types and their manifestations irrespective of
the origin of the ailment in a subject in need thereof
including humans and other mammals. It is contemplated
that the inventive compositions can be employed for pre
venting and/or treating other conduction disturbances of the
central nervous system (CNS), and the emotional, cognitive,
and motor symptoms resulting there from.

electroconvulsion, of either or both an acute or chronic

nature, of unknown origin or secondary to conditions such
as, but not limited to: surgery, irradiation, or other manipu

lent of its pharmaceutically acceptable salt.
Additional advantages of the present invention Will

lation of the brain and/or CNS; alcohol, benZodiaZepine,

become readily apparent to those skilled in the art from this
30

its several details are capable of modi?cations in various

obvious respects, all Without departing from the present

barbiturate or other drug or chemical WithdraWal; exposure
to epileptogenic drugs and/or chemicals; acute or chronic
injury or trauma; stroke or cerebrovascular accident; fever;
meningitis or other CNS in?ammation or infection; or

electroconvulsive therapy.
In practicing the present invention, the compound having

invention.
35

The present invention relates to therapeutic bridged

formula (I) or a pharmaceutically acceptable salt or complex

thereof is formulated into pharmaceutical compositions. In
an embodiment of the present invention, 4,4'-thiodianiline,

4,4'-diaminobenZophenone, 4,4'-diaminodiphenyl ether,

dianilino compounds and their pharmaceutical compositions

4,4'-methylenedianiline, or (3-aminophenyl)-(4-aminophe
nyl) amine are formulated into pharmaceutical compositions

and method of use thereof for the prevention and treatment

of epilepsies, seizures, and other electroconvulsive disor
ders. The therapeutic compound comprises a compound

formulated

In an embodiment of the present invention, the inventive
compositions are administered to a subject in need thereof to
prevent or treat disturbances of the CNS, such as seiZure and

to 300 mg/kg of 4,4'-thiodianiline, 4,4'-diaminobenZophe

DESCRIPTION OF THE INVENTION

are

It has been discovered that the inventive compositions are

an effective amount of 4,4'-thiodianiline, 4,4'-diaminodiphe

folloWing detailed description. As Will be realiZed, the
invention is capable of other and different embodiments, and

amine

pharmaceutically acceptable carrier.

nyl ether, 4,4'-diaminobenZophenone, 4,4'-methylenedi

or (3-aminophenyl)-(4-aminophenyl) amine or the equiva

4,4'-methylenedi

pharmaceutical preparation comprising the active agent or a
pharmaceutically acceptable salt or complex thereof and a

a pharmaceutically acceptable carrier, adjuvant or vehicle.
Still further according to the invention, the foregoing
objects and advantages for the treatment or prevention of
electroconvulsive disorders are achieved by administering

pharmaceutically acceptable salt or complex thereof and in
a pharmaceutically accepted carrier, adjuvant or vehicle.

4,4'-diaminobenZophenone,

aniline, 4,4'-diaminodiphenyl ether, and (3-aminophenyl)

and advantages for the treatment or prevention of electro
convulsive disorders are achieved by administering a phar
maceutical composition comprising an effective amount of
the therapeutic compound to mammals in an admixture With

40

The compound of formula (I) includes all resolved enan

tiomers, diastereoisomers, tautomers, salts, solvates and
polymorphic forms thereof. Salt forms of 4,4'-thiodianiline,

having the folloWing formula (I):

4,4'-diaminobenZophenone, 4,4'-diaminodiphenyl ether,
4,4'-methylenedianiline, or (3-aminophenyl)-(4-aminophe
45

nyl) amine include, but are not limited to the folloWing:

inorganic acid addition salts such as hydrochloride, hydro

bromide, sulfate, phosphate and nitrate; organic acid addi
tion salts such as acetate, galactarate, propionate, succinate,
50

lactate, glycolate, malate, tartrate, citrate, maleate, fumarate,
methanesulfonate, salicylate, p-toluenesulfonate, benZene
sulfonate, and ascorbate; salts With acidic amino acids such

Wherein R1, R2, R3, and R4, are each independently selected
from the group consisting of hydrogen, hydroxy, amino,
phenyl, substituted or unsubstituted Cl_l0 alkyl, C3_1O
branched alkyl, substituted or unsubstituted C3_8 cycloalkyl,

as aspartate and glutamate; the salts may in some cases by
hydrates or solvates With alcohols and other solvents. Salt

forms of 4,4'-thiodianiline, 4,4'-diaminobenZophenone, 4,4'
55

substituted or unsubstituted arylalkyl (comprising Ari
(CH2)n; Where Ar is aromatic and n:0-l0) substituted or
unsubstituted Cl_1O alkoxyl, substituted or unsubstituted

solvent, With or Without alcohols or Water.

The compounds of the present invention are useful in

pharmaceutical compositions for systemic administration to

C 1_ 1O acyl, Where the substituents are, but are not limited to,

substituents selected from the group consisting of halogen,

mammals including humans as a single agent, or as a
60

phenyl, thio, amino, hydroxyl, hydroxylamino, nitrile, car

boxyl, amido, phosphate, sulfate, sulfonamide, nitroso,
nitrone, aZido, imino, hydraZine, guanidino, oxyguanidino,
methylguanidino, hydroxyguanidino, aminoguanidino,
thioguanidino, amidino, oxyamidino, ureido, thioureido,

methylenedianiline, or (3-aminophenyl)-(4-aminophenyl)
amine, can be prepared by mixing the acid in a conventional

primary or adjunct agent With any other medication, chemi
cal, drug or non-drug therapy, or combination thereof.
The aforementioned administration of 4,4'-thiodianiline,

4,4'-diaminobenZophenone, 4,4'-methylenedianiline, 4,4'
diaminodiphenyl ether, or (3 -aminophenyl)-(4-aminophe

thioamido, and nitro; and X is selected from the group

nyl) amine, or pharmaceutically acceptable salts or com
plexes thereof is to be employed acutely, or as a single dose,

consisting of 40*, iSi, iN(H)i, iSei, iSii,

or administered intermittently, or on a regular schedule of

65
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5
By “e?‘ective amount,

unspeci?ed duration, or by continuous infusion of unspeci
?ed duration, by an acceptable route of administration

therapeutic amount,

therapeu

tic e?‘ective amount” or “e?‘ective dose” is meant that the
amount su?icient to elicit the desired pharmacological or

including, but not limited to, the oral, buccal, intranasal,

pulmonary, transdermal, rectal, vaginal, intradermal, intrath

therapeutic e?‘ect, thus resulting in e?‘ective prevention or

ecal, intravenous, intramuscular, and/or subcutaneous

treatment of the condition or disorder. Thus, When treating
a CNS disorder, an effective amount of compound is that

routes.

amount su?icient to pass across the blood-brain barrier of

The pharmaceutical preparations can be employed in unit

the subject to interact With relevant receptor sites in the brain
of the subject. Prevention of the condition or disorder is
manifested by delaying the onset of the symptoms of the

dosage forms, such as tablets, capsules, pills, poWders,
granules, suppositories, sterile and parenteral solutions, or
suspensions, sterile and non-parenteral solutions or suspen

condition or disorder. Treatment of the condition or disorder

sions, oral solutions or suspensions, oil in Water or Water in

is manifested by a decrease in the symptoms associated With

oil emulsions and the like, containing suitable quantities of

the condition or disorder, or an amelioration of the recur

an active ingredient. Topical application can be in the form

rence of the symptoms of the condition of disorder.
The e?‘ective dose can vary, depending upon factors such

of ointments, creams, lotions, jellies, sprays, douches, and
the like. For oral administration either solid or ?uid unit

as the condition of the patient, the severity of the symptoms
of the disorder, age, Weight, metabolic status, concurrent
medications, and the manner in Which the pharmaceutical
composition is administered. Typically, the e?‘ective dose of

dosage forms can be prepared With the compounds of
Formula I.
Either ?uid or solid unit dosage forms can be readily
prepared for oral administration. For example, the com
pounds can be mixed With conventional ingredients such as

compounds generally requires administering the compound
20

in an amount of about 0.1 to 500 mg/kg of the subject’s
Weight. In an embodiment of the present invention, a dose of
about 0.1 to about 300 mg/kg is administered per day
inde?nitely or until symptoms associated With the condition
or disorder cease. Preferably, about 1.0 to 50 mg/kg body

25

Weight is administered per day. The required dose is less
When administered parenterally.

dicalciumphosphate, magnesium aluminum silicate, magne
sium stearate, calcium sulfate, starch, talc, lactose, acacia,
methylcellulose and functionally similar materials as phar
maceutical excipients or carriers. A sustained release for

mulation may optionally be used. Capsules may be formu
lated by mixing the compound With a pharmaceutical diluent
Which is inert and inserting this mixture into a hard gelatin
capsule having the appropriate siZe. If soft capsules are
desired, a slurry (or other dispersion) of the compound, With
an acceptable vegetable, light petroleum or other inert oil
can be encapsulated by machine into a gelatin capsule.
Suspensions, syrups, and elixirs may be used for oral
administration of ?uid unit dosage forms. A ?uid preparation
including oil may be used for oil soluble forms. A vegetable
oil, such as corn oil, peanut oil, or sal?oWer oil, for example,
together With ?avoring agents, sWeeteners, and any preser
vatives produces an acceptable ?uid preparation. A surfac

EXAMPLE 1
30

clonic seiZures that identi?es compounds that prevent sei
Zure spread. The MES model is highly reproducible and has
a consistent endpoint. An advantage of this model is that the
behavioral and electrographic seiZures are consistent With

those observed in humans [2].

tant may be added to Water to form syrup for ?uid dosages.

In the MES test, the animal receives an electrical stimu

Hydro-alcoholic pharmaceutical preparations may be used
that have an acceptable sWeetener, such as sugar, saccharine,
or a biological sWeetener and a ?avoring agent in the form
of an elixir.

Pharmaceutical compositions for parental and suppository
administration can also be obtained using techniques stan
dard in the art. Another preferred use of these compounds is
in a transdermal parenteral pharmaceutical preparation in a
mammal such as a human.

The above and other drugs can be present in the reservoir
alone, or in combination form With pharmaceutical carriers.
The pharmaceutical carriers acceptable for the purpose of
this invention are the art knoWn carriers that do not

adversely affect the drug, the host, or the material compris
ing the drug delivery device. Suitable pharmaceutical car
riers include sterile Water, saline, dextrose, dextrose in Water
or saline, condensation products of castor oil and ethylene
oxide combining about 30 to about 35 moles of ethylene
oxide per mole of castor oil, liquid acid, loWer alkanols, oils
(such as corn oil, peanut oil, sesame oil and the like), With
emulsi?ers such as mono- or di-glyceride of a fatty acid or

a phosphatide (e.g., lecithin and the like), glycols, poly

The Maximal Electroshock SeiZure (MES) or Maximal
SeiZure Pattern Test
The MES is an experimental model for generaliZed tonic

lus, 0.2 seconds in duration, via corneal electrodes primed
40

With an electrolyte solution containing an anesthetic agent.
The 0.2 second stimulation is generated With 150 mA in rats
and 50 mA in mice at 60 HZ. Rats, Weighing betWeen 105 g
and 130 g, and mice, Weighing betWeen 18 g and 25.5 g,
receive an electrical stimulus 15 minutes, 30 minutes, 1
hour, 2 hours, and 4 hours after administration of the test

compound. In rats, the compound is administered orally,
While mice receive the agent via intraperitoneal injection.
The test endpoint, electrogenic seizure, is manifested as
hindlimb tonic extension. Inhibition of hindlimb tonic exten
sion indicates that the test compound is able to inhibit

MES-induced seiZure spread and therefore may have anti
seiZure activity [2-4]. The results of the MES test suggest
that this class of compounds is e?‘ective in preventing
seiZure spread in both rats and mice (Tables 1 and 2).
TABLE 1
Percentage of mice in Which 30, 100, or 300 mg/kg of the
test compound prevented MES-induced seizure 0.5 or
4 hours after intraperitoneal administration.

alkyne glycols, aqueous media in the presence of a suspend

ing agent (for example, sodium carboxymethylcellulose),
sodium alginate, poly(vinylpyrolidone), and the like (alone
or With suitable dispensing agents such as lecithin), or
polyoxyethylene stearate and the like. The carrier may also

contain adjuvants such as preserving, stabiliZing, Wetting,
emulsifying agents and the like together With the penetration
enhancer of this invention.

Test Compound

0.5 h

4.0 h

(%)

(%)

0
66
100

0
100
100

4,4'—thiodianiline
30 mg/kg
100 mg/kg
300 mg/kg

US 7,226,949 B2
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TABLE l-continued

TABLE 3-continued

Percentage of mice in Which 30, 100, or 300 mg/kg of the
test compound prevented MES-induced seizure 0.5 or
4 hours after intraperitoneal administration.

ED5O required to inhibited MES-induced seizure at
the time of peak effect in rat after oral administration
of the test compound

Test Compound

0.5 h

4.0 h

(%)

(%)

5

Time to Peak Effect

ED5O

(hours)

(mg/kg)

2

31.74 1 24.42

Test Compound

4,4'—methylenedianiline

(3—aminophenyl)-

10 (4-aminophenyl) amine
30 mg/kg
100 mg/kg
300 mg/kg

0
100
100

0
0
100

4,4'—diaminobenzophenone

EXAMPLE 2

30 mg/kg

0

0

100 {Hg/kg

100

100

300 mg/kg

100

100

15

6 Hz Kindling Model
_

4,4'-dia_minodiphenyl ether

_

_

_

_

The 6 Hz k1ndl1ng model 15 another experimental se1zure

model that effectively detects compounds With anti-seizure
30 mg/kg
100 mg/kg
300 {Hg/kg

0
100
100

0
100
100

20

(3_aminophenyl)_
(4-aminophenyl) amine

activity. This screen is used to evaluate the ability of a
. . .
.
I .
compound to prevent the acqu1s1t1on of focal selzures, 1n

particular, the capacity of a compound to prevent the devel
opment of seizures induced by a low-frequency (6 Hz), long
duration (three seconds) stimulus in electrode implanted rats

138 251;:

108

108

25 is evaluated [5]. Several of the most promising compounds

300 mg/kg

100

100

Were evaluated in this screen to further characterize their

anti-seizure activity.
In the 6 Hz kindling test, mice are implanted With corneal
electrodes. The test compound is administered (i.p.) to the
30 animal at 0.25, 0.5, 1, 2, or 4 hours prior seizure induction.

TABLE 2
Pmmtag? of rats in which 30 {mg/kg of th? Est

The seizure is initiated by delivering a current (32 mA at 6

compound prevented MES-induced seizure 0.25,

Hz for three seconds) to the animal through the corneal

0-5 1-0 2-0 or 4-0 hours aim Oral administration

Test Compound

electrodes. The resulting psychomotor seizure is usually

025 h

OIS h

10 h

ZIO h

4I0 h

(%)

(%)

(%)

(%)

(%)

4’4'?nodlamhn? . .

100

100

100

100

100

4,4'—methylened1an1l1ne

100

75

92

100

50

4I4._diaminob?nzoph?nom

50

100

75

100

75

4,4'—diaminodiphenyl ether

100

100

75

75

100

0

50

75

50

50

(30 {mg/kg)
I

I

characterized by a mrmmal Iclon1c phase followed by ste
35 reotyped, automat1st1c behavlors. ThlS response is analogous

I I

to the aura of human patients With partial seizures. If the

gi'?i?gp?z?yg'mme
p y

animal does not exhibit this behavior, the test compound is
.

.

Se1Zl1I'e properties.

40

A full dose-response curve Was also generated in rats to

The data in Table 4 clearly indicates the capacity of
4,4'-thiodianiline, 4,4'-diaminobenzophenone, and 4,4'-me
thylenedianiline to inhibit 6 Hz seizures. 4,4'-Thiodianiline
Was the most e?ecnve Compound evaluated’ havlng an EDso

determine the ED5O value (n:8 at each time point). These 45 game get?veen 30 anddso
experiments Were conducted at the compound’s time of peak
.

_

. .

_

.

_

dgse 9f 109

our 0, t e Compoun S teste

1

He

211%

selzure 1n

_ _ 0 O

the ammals tested 0.25, 0.5 and 1.0 hours after admlmstra

pharmacodynamrc act1v1ty and the results are shown in
|

.

cons1dered to have protected the ammal and have ant1

.

_

non of the compound.

Table 3. 4,4 -D1am1nod1phenyl ether Was the most active

compound (EDSO: 5.24:4.67 mg/kg) and also had the long-

TABLE 4

est t1me to peak effect (6 hours). The ED5O of 4,4'-th1od1- 50
aniline Was evaluated in both rats and mice. In rats, 1 hour
.

.

.

'

.

.

P?rc?nmg6 of Mm in Which Exposure to th? T?st Compound

. .

Prevented Seizure in the 6 Hz Test at 0.25, 0.5, 1.0, 2.0 and

after oral admrmstratron, 4,4 -th1od1an1l1ne had an EDsoIof
6.60:5.07 mg/kg, and 0.5 hours after mtrapentoneal adm1n
istration in mice it had an ED5O of 5342:1492 mg/kg.

4I0 Hours a?er intmperitoneal Admini nation
55 Test Compound

TABLE 3

0'25 h

0'5 h

1'0 h

2'0 h

4'0 h

0
100
100

25
100
100

25
100
100

25
75
100

ND
0
0

ND

(%)

(%)

(%)

(%)

(%)

4,4'-thiodianiline

ED5O required to inhibited MES-induced seizure at
the time of peak effect in rat after oral administration
of the Est compound

30 mgkg
80 mgkg
100 mg/kg
60

Time to Peak Effect

ED5O

Test Compound

(hours)

(mg/kg)

4,4'—thiodianiline

1

6.60 r 5.07

4,4'—methylenedianiline
4,4'-diaminobenzophenone
4,4'—diaminodiphenyl ether

1
1
6

10.63 1 5.88
7.15 r 1.89
5.24 r 4.67

,

.

.

4,4 —d1am1nobenzophenone
30 mgkg

65

0

0

0

ND

100 mg/kg
4,4'—diaminodiphenyl ether

100

100

100

0

30 mgkg
100 mgkg

0
100

50
100

25
100

25
100

0

ND
0

US 7,226,949 B2
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TABLE 4-continued

below. The Racine seizure scores dropped from between a
stage 4 and stage 5 seizure for control measurements to
between a stage 1 and stage 2 seizure after treatment with

Percentage of Mice in which Exposure to the Test Compound
Prevented Seizure in the 6 Hz Test at 0.25, 0.5, 1.0, 2.0 and
4.0 Hours after intraperitoneal Administration

4,4'-thiodianiline.
TABLE 5

0.25 h

0.5 h

1.0 h

2.0 h

4.0 h

(%)

(%)

(%)

(%)

(%)

Test Compound

Racine Seizure Scores and Afterdischarge Durations
Following Stimulation, for Rats Treated with 100 mgkg

4,4'—methylenedianiline

of4 4'—Thiodianiline.

30 mg/kg
100 mg/kg

0
100

0
100

0
100

ND
0

ND
0

Hippocampal Kindling Model

(sec) 1 SEM

Control
15

4.86 z 0.14
1.43 z 081*

72.57 1 7.20
19.14 1 9.58*

1.29 z 084*
1.29 z 0.64*
1.57 z 081*

25.29
24.86
33.29
34.71

:13.71*
1 11.43*
:14.17*
:14.35*

1.57
1.57
1.86
1.86

57.43
55.29
71.29
65.43

1
1
1
1

165
195
225
255

The hippocampal kindling model is an experimental sei
zure model used to simulate focal seizures. This model

evaluates the capacity of a compound to affect both the

expression and acquisition of focal seizures. In addition,

0.71 z 0.57*

z
z
z
z

0.65*
0.69*
0.70*
0.63*

18.17
18.19
18.99
17.91

*Signi?cantly different than control

kindled seizures provide a methodology for studying com
plex brain networks that may contribute to the spread and
generalizations of seizures from a focus. The hippocampal

Using the data generated from each of the doses, 4,4'
25

kindling models that can evaluate the temporal effects of an

agent in a single animal [6,7]. For this assessment, bipolar
electrodes are surgically implanted in the ventral hippocam
pus of adult male Sprague-Dawley rats (275-300 g) under
ketamine-xylazine anesthesia. Following a one-week recov

Afterdischarge Duration

Score 1 SEM

45
75
105
135

EXAMPLE 3

kindling model has the advantage of being one of the only

Racine Seizure
Time (min)

30

ery period, stage ?ve behavioral seizures are induced by
stimulating the rat 12 times per day with 50 Hz, 10 5 train
of 1 ms biphasic 200 [1A pulses delivered every 30 min for
six hours on alternating days. After ?ve stimulus days, the
animal has had 60 stimulations. A drug free control period
with supramaximal stimulations is used to verify the stabil
ity of a stage ?ve generalized seizure before the anticon
vulsant activity of a drug is measured.

thiodianiline, was found to have an ED5O of 51.43 mg/kg.

This is the dose of 4,4'-thiodianiline required to prevent the
expression of focal seizures in this model. The capacity of
4,4'-thiodianiline to elevate afterdischarge threshold and
decrease afterdischarge duration suggests that it possess the
ability to limit focal seizure activity originating from the

ventral hippocampus.
4,4'-Diaminobenzanalide and 4,4'-diaminodiphenyl ether
were also evaluated in the hippocampal kindling model.
While these compounds were not as effective as 4,4'-thio

dianiline, they also had the capacity to block the expression
of fully kindled seizures.
EXAMPLE 4

This screen is used to measure the capacity of the drug to

prevent the expression of focal seizures. During a drug trial,
the afterdischarge threshold of each animal is determined by
increasing the current intensity, stepwise, until the rat dis
plays an electrographic afterdischarge lasting at least four

Minimal Neurotoxicity
Toxicity in mice and rats is assessed using three screens:
the rotorod in mice, positional sense and gait in rats. In mice,
the test compound is administered at doses of 30, and 100
mg/kg prior to evaluation in the toxicity screens. The mice

seconds. The animal is exposed to an initial stimulation of 20

[1A, the stimulation is increased in 10 uA increments every
one-two minutes until an afterdischarge is recorded. After

45

the stability of the stage ?ve seizure is established, the drug

pound is administered at 30 mg/kg prior to the toxicity

candidate is administered to the rats via intraperitoneal
injection 15 minutes after the last control stimulation. Start

ing with the ?rst dose, the anticonvulsant activity of the test
agent is measured every thirty minutes for four hours.
Following each stimulation, Racine seizure scores and after
discharge durations [8] are compared to control values to
quantify the anti-convulsant activity of the agent. The

assessment. The rats are tested at 0.25, 0.5, 1, 2, and 4 hours
after oral administration of the test compound. In rats, a
series of doses were tested at the time to peak effect to
50

Racine seizure scores vary from stage 1 to 5. The stages are

Toxicity in mice weighing between 18 and 25.5 g is
assessed using the standardized rotorod test [9]. For each
compound tested, a minimum of 18 animals are evaluated

nodding, Stage 3istage 2 and forelimb clonus, Stage
4istage 3 and rearing, Stage 5istage 4 and repeated

for neurotoxicity. Control mice can maintain their equilib
rium for an extended period of time when they are placed on
a 6-rpm rotation rod. Neurologically impaired animals can
not maintain equilibrium for one minute in each of three
successive trials.

rearing and falling [8]. Since a single animal is used, each rat
serves as its own control.

4,4'-Thiodianiline was used in the rat hippocampal
kindled rats to screen to measure its anticonvulsant poten

afterdischarge durations were measured and are shown

determine the toxicity ED5O at this timepoint.
Rotorod Test

characterized according to the following criteria: Stage
limouth and facial clonus, Stage 2istage 1 and head

tial. Doses of 12.5, 25, 50 and 100 mg/kg were evaluated at
a minimum of seven time points (n:7 for each dose and each
time point). Table 5 shows the raw data from a 100 mg/kg
dose of 4,4'-thiodianiline. After oral administration of the
test compound stimulation, the Racine seizure scores and

are tested at 0.5 hours and 4 hours after intraperitoneal
administration of the test compound. In rats, the test com

Positional Sense Test
65

Behavioral toxicity in twenty rats weighing between 105
and 130 g is assessed by the positional sense test. In this test,
one hind leg is gently lowered over the edge of a table. If the

US 7,226,949 B2
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rat experiences neurological toxicity, it Will not be able to
quickly lift its leg quickly back to a normal position.

described With respect to particular embodiments, it should

Gait and Stance Test

be readily apparent that modi?cations can be made Within
the spirit and scope of the invention, and it is therefore not

While the salient features have been illustrated and

desired to limit the invention to the exact details shoWn and
described.
What is claimed is:

In the gait and stance test, neurotoxicity is indicated by a
circular or zigzag gait after administration of the test com

pound. In addition, ataxia, abnormal spread of the legs,

1. A method of treating and ameliorating epilepsy, seizure

abnormal posture, tremor hyperactivity, lack of exploratory

or electroconvulsive disorders in mammals Which comprises
administering a therapeutic effective amount to said mam

behavior, somnolence, stupor, or catalepsy can indicate
neurotoxicity. This toxicity test Was conducted on rats,
Weighing betWeen 105 and 130 g.
The acute neurotoxicity of this class of compounds Was
shoWn to be Well above the doses required for therapeutic

mal of the folloWing therapeutic compound, including
resolved enantiomers, diastereomers, salts, solvates and
polymorphic froms thereof, having the folloWing formula

(1)1

bene?t. No acute neurotoxicity Was observed as measured

by the rotorod test up to four hours after mice had been given
4,4'-thiodianiline, even at doses as high as 300 mg/kg. In

rats, 1 hour (the time to peak effect) after oral administration
of 4,4'-thiodianiline, the ED5O for toxicity Was determined to
be almost 60 times greater than the ED5O for anti-convulsant
activity. Similarly, 4,4'-diaminobenzophenone Was not neu
rotoxic to rats. None of the rats tested at any timepoints (0.25
to 24 hours after oral administration of 4,4'-diaminoben
zophenone) shoWed acute neurotoxic elfects, even at doses
as high as 500 mg/kg. In contrast, the ED5O for anti

convulsant activity for 4,4'-diaminobenzophenone in rats
Was 7.15 mg/kg. In mice, 4,4'-diaminobenzophenone
shoWed no neurotoxicity at doses beloW 100 mg/kg. 4,4'
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Diaminodiphenyl ether, 4,4'-methylenedianiline and (3-ami
nophenyl)-(4-aminophenyl) amine had no signi?cant toxic
ity even at 100 mg/kg in mice and 250 mg/kg in rats.
These data suggest that the acute neurotoxicity levels of
these compounds in mice and rats, as assessed by the rotorod
test, the positional sense and the gait and stance tests, far
exceed the level required for anticonvulsant activity.
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11. The method of claim 1, Wherein the therapeutic
effective amount is from about 1 mg/kg to about 40 mg/kg.
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